SeekingAlpha · Oct 28, 2026
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market
Compass Pathways is initially targeting the TRD market, which is large and underserved. Find out why CMPS stock is a Buy.
CM
NASDAQ · CMPS
COMPASS Pathways plc
Healthcare · Medical - Care Facilities
$8.59
Up+$0.01 (+0.12%)
Updated Nov 4, 2026, 5:33 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 667.21M
- P/E ratio
- -2.79
- Dividend yield
- 0.00%
- 52-week range
- $4.88 – $15.87
- Volume
- 8.85M
- Avg. volume
- 1.76M
Price performance · CMPS
CMPS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CMPS closed at $8.59 after 21 trading sessions, down 25.69% for the selected period.
- Last close
- $8.59
- Period change
- -25.69%
- Period low
- $8.41
- Period high
- $12.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $9.00 | $9.49 | $8.47 | $8.59 | 8.85M |
| Nov 2, 2026 | $11.71 | $11.76 | $7.54 | $8.41 | 16.85M |
| Oct 30, 2026 | $11.822 | $11.9932 | $11.27 | $11.57 | 2.18M |
| Oct 29, 2026 | $12.37 | $12.50 | $11.97 | $12.19 | 1.38M |
| Oct 28, 2026 | $11.85 | $12.31 | $11.71 | $12.28 | 1.42M |
| Oct 27, 2026 | $11.10 | $11.84 | $11.00 | $11.81 | 2.28M |
| Oct 26, 2026 | $11.285 | $11.36 | $10.94 | $11.05 | 1.52M |
| Oct 23, 2026 | $11.45 | $11.515 | $11.02 | $11.18 | 1.16M |
| Oct 22, 2026 | $11.73 | $11.9699 | $11.4299 | $11.63 | 1.34M |
| Oct 21, 2026 | $12.00 | $12.12 | $11.77 | $11.84 | 1.83M |
| Oct 20, 2026 | $11.11 | $12.0441 | $11.065 | $11.90 | 3.35M |
| Oct 19, 2026 | $10.87 | $11.17 | $10.81 | $11.11 | 3.28M |
| Oct 16, 2026 | $11.51 | $11.60 | $10.72 | $10.75 | 4.97M |
| Oct 15, 2026 | $11.25 | $11.695 | $11.15 | $11.62 | 2.81M |
| Oct 14, 2026 | $11.09 | $11.50 | $10.97 | $11.27 | 2.54M |
| Oct 13, 2026 | $11.54 | $11.54 | $11.11 | $11.14 | 1.88M |
| Oct 12, 2026 | $12.02 | $12.05 | $11.53 | $11.53 | 1.96M |
| Oct 9, 2026 | $11.685 | $12.075 | $11.42 | $12.00 | 2.28M |
| Oct 8, 2026 | $11.695 | $11.79 | $11.1304 | $11.47 | 2.83M |
| Oct 7, 2026 | $11.50 | $11.86 | $11.45 | $11.69 | 1.59M |
| Oct 6, 2026 | $11.72 | $11.80 | $11.17 | $11.56 | 2.8M |
Latest CMPS news
The latest Smart Investors Daily articles mentioning CMPS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CMPS research
Overview
Company profile and research snapshot.
Company profile
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2026 | BTIG | Buy | — |
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Morgan Stanley | Overweight | — |
| Aug 6, 2026 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
LONDON & JERSEY CITY, N.J., October 27, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026.
Yahoo · Oct 21, 2026
Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances
Cybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026. Helus Pharma Chief Executive Officer Michael Halstead said the company is developin
SeekingAlpha · Oct 21, 2026
Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales
COMPASS Pathways is rated buy, with high risk, based on strong trial design and imminent FDA review for COMP360. Read more on CMPS stock here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
